Friday, March 26, 2010

Reaction to story about Avandia studies

A few days ago, I provided some links to a story that revealed that many of the academic reports on Avandia had been prepared by people with ties to its manufacturer. As you would expect, that story has generated some reaction from many different sources. states that "[i]n a blistering editorial, writers for the Journal of the American Medical Association (JAMA), lambasted GlaxoSmithKline’s activities in research over potential side effects of Avandia, which some say are responsible for tens of thousands of heart attacks and deaths. The authors are calling for new, stringent, medical and scientific journal reforms that would ensure integrity and minimize the ability of corporations to obfuscate scientific data." For that full story go here. The JAMA editorial is available here. In a similar story, Pharmalot is reporting that "[i]n a stern editorial, the editors of the Journal of the American Medical Association write that industry-sponsored research should be analyzed by researchers without ties to the drugmaker that is developing the medicine being studied." To read that story go here. Finally, a similar story- with more links - can be found in the Drug Recall Lawyer Blog.

No comments: